Abstract
Induction chemotherapy with Genexol-PM and cisplatin demonstrated modest tumor response in locally advanced head and neck squamous cell carcinoma.Considering favorable toxicity profiles and promising survival data, further studies on this regimen are warranted in patients with head and neck squamous cell carcinoma. Genexol-PM is a polymeric micellar formulation of paclitaxel without Cremophor EL. We investigated the efficacy and safety of Genexol-PM plus cisplatin as induction chemotherapy (IC) in patients with locally advanced head and neck squamous cell carcinoma (LA-HNSCC). Patients received Genexol-PM (230 mg/m2) and cisplatin (60 mg/m2) every 3 weeks as IC. After three cycles of IC, definitive treatment of either concurrent chemoradiotherapy (CCRT) with weekly cisplatin (30 mg/m2) or surgery was performed. The primary endpoint was overall response rate (ORR) after IC. Of 52 patients enrolled, 47 completed three cycles of IC, and the ORR was 55.8% (95% confidence interval, 42.3-69.3). Although there was one treatment-related death, toxicity profiles to Genexol-PM and cisplatin were generally favorable, and the most common grade 3 or 4 toxicities were neutropenia (15.4%), anorexia (7.7%), and general weakness (7.7%). Fifty-o...Continue Reading
References
Feb 3, 2000·Journal of the National Cancer Institute·P TherasseS G Gwyther
Jun 3, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Tae-You KimYung-Jue Bang
Nov 9, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ricardo HittHernán Cortés-Funes
Sep 6, 2007·Annals of Oncology : Official Journal of the European Society for Medical Oncology·D-W KimD S Heo
Oct 26, 2007·The New England Journal of Medicine·Jan B VermorkenUNKNOWN EORTC 24971/TAX 323 Study Group
Oct 26, 2007·The New England Journal of Medicine·Marshall R PosnerUNKNOWN TAX 324 Study Group
Sep 12, 2008·The New England Journal of Medicine·Robert I Haddad, Dong M Shin
May 19, 2009·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·Jean-Pierre PignonUNKNOWN MACH-NC Collaborative Group
Jul 28, 2009·Annals of Oncology : Official Journal of the European Society for Medical Oncology·W T LimB Chowbay
Jun 10, 2010·The New England Journal of Medicine·K Kian AngMaura L Gillison
Feb 19, 2013·The Lancet Oncology·Robert HaddadMarshall Posner
Jul 10, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Pierre BlanchardUNKNOWN Meta-Analysis of Chemotherapy in Head and Neck Cancer, Induction Project, Collaborative Group
Nov 22, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·R HittUNKNOWN Spanish Head and Neck Cancer Cooperative Group (TTCC)
Jul 23, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ezra E W CohenEverett E Vokes
Mar 19, 2015·Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]·Zoltán Takácsi-NagyMiklós Kásler
Jun 25, 2015·Head & Neck·Chan-Young OckDae Seog Heo
Aug 26, 2015·The Oncologist·Keun-Wook LeeDae Seog Heo
Oct 21, 2015·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Hae Su KimMyung-Ju Ahn
Nov 20, 2015·Cancer Research and Treatment : Official Journal of Korean Cancer Association·Ryul KimDae Seog Heo
Sep 14, 2016·Cancer Research and Treatment : Official Journal of Korean Cancer Association·In Hae ParkJungsil Ro
Mar 23, 2017·Cancer Research and Treatment : Official Journal of Korean Cancer Association·Shin-Wha LeeSoon Beom Kang
Sep 16, 2017·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M G GhiUNKNOWN GSTTC (Gruppo di Studio Tumori della Testa e del Collo)
Italian Study Group
Citations
Nov 26, 2019·Natural Product Reports·April L Risinger, Lin Du
Nov 3, 2020·International Journal of Nanomedicine·Ruben A G van EerdenStijn L W Koolen
Aug 11, 2021·Seminars in Cancer Biology·Xin SuHongcai Shang
Aug 29, 2021·Pharmaceutics·Lu TangWei Wang